Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 1 (10%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.3% |
| SASAN, ARADHANA | 1 | 64.3% | +26.6% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| RICCI, CRAIG D | 1 | 53.5% | +52.6% |
| JARRELL, NOBLE E | 1 | 80.9% | +9.6% |
| MAYHEW, BRADLEY SCOTT | 1 | — | — |
| ALLEN, SARAH ELIZABETH | 1 | 60.9% | +45.0% |
| MCKILLOP, JOHN CHARLES | 1 | 56.3% | +40.7% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.9% | +41.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 22d |
| 18005800 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A | ALLEN, SARAH ELIZABETH | 83d |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 22d |
| 17906893 | KCNT1 INHIBITORS AND METHODS OF USE | ROBINSON, MIKHAIL O'DONNEL | 22d |
| 18005800 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A | ALLEN, SARAH ELIZABETH | 83d |
| 19540291 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | SASAN, ARADHANA | — |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | — |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
| 17924255 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SYNGAP1 | MCKILLOP, JOHN CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1637 | 2 |
| 1615 | 1 |
| 1628 | 1 |
| 1699 | 1 |
| 1621 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19540291 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | SASAN, ARADHANA | 1615 | DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | 1628 | §103DPOther | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — | §102§103 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | — | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Non-Final OA | 22d | Pending | Aug 17, 2023 |
| 18036074 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | MAYHEW, BRADLEY SCOTT | 1621 | §103 | Non-Final OA | — | Pending | May 09, 2023 |
| 18005800 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A | ALLEN, SARAH ELIZABETH | 1637 | §103§112 | Non-Final OA | 83d | Pending | Jan 17, 2023 |
| 17924255 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SYNGAP1 | MCKILLOP, JOHN CHARLES | 1637 | §103 | Non-Final OA | — | Pending | Nov 09, 2022 |
| 17906893 | KCNT1 INHIBITORS AND METHODS OF USE | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 22d | Pending | Sep 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial